Aortic Stent Grafts Market Size, Trends & Demand 2034

The Aortic Stent Grafts Market was valued at US$ 2,763.37 million in 2025 and is projected to reach US$ 5,103.48 million by 2034. The market is expected to register a CAGR of 7.1% during 2026–2034. Expansion is being witnessed through an increased uptake of endovascular aneurysm repair, improved availability of anatomic grafts and increased demand for minimally invasive treatments in abdominal and thoracic aortic aneurysms.

North America remains the principal commercial and clinical centre, with the regional market expected to expand at a CAGR of 7.0–7.4% through 2034. The Aortic Stent Grafts industry in the region has been bolstered by proven aneurysm screening programs, large vascular centers, better reimbursement for procedures and quick adoption of branched, tapered and low-profile stent grafts among patients with complicated anatomy.

Aortic Stent Grafts Market Assessment and Insights

The technology has advanced from standardized infrarenal devices to reduced-profile systems that adapt to anatomy in terms of repositionability, active fixation, control of deployment and branched or fenestrated types. This makes manufacturing processes difficult since it needs accurate nitinol processing, consistent graft material quality, effective sterilization and a wide range of sizes. Current devices account for tapered vessels, shortened landing zones, iliac artery access challenges, branch protection and imaging-based planning to bridge clinical decision making and device manufacturing and stocking.

Future growth will come increasingly from healthcare systems in Asia Pacific, Latin America and certain Middle Eastern countries adopting hybrid operating rooms and specialist vascular practices. Acceptance of real-world evidence and post approval surveillance by regulators could cut down learning curve without compromising safety needs. Capital investment will be oriented towards production of custom devices, medical education, clinical registries and planning tools. These investments would help increase the number of patients anatomically eligible and expand the use of the endovascular approach beyond traditional infrarenal aneurysms to other diseases including arch, dissection and thoracoabdominal aneurysms.

Aortic Stent Grafts Market Report Scope

Aortic Stent Grafts Market Analysis

Growth in the Aortic Stent Grafts Market occurs through increased use of endovascular procedures among high risk patients that cannot tolerate open surgery. Demand is driven by vascular surgeons, cardiovascular specialists, imaging labs, graft makers, catheter makers, distributors and purchasing from hospitals. Computed tomography angiography continues to be integral to sizing and planning, and therefore capacity in this technology is one of the key determinants of the addressable volume of procedures.

Supply-side considerations include strict quality demands, lengthy regulatory cycles, and the need to provide an extensive array of stent graft sizes, lengths, limbs, cuffs and extensions. Availability of nitinol, woven polyester or expanded polytetrafluoroethylene processing capability, sterilization capacity, and traceability affect manufacturing capacity. The hospitals will also need assured case support since errors in sizing, delivery difficulties and lack of components can have consequences.

From the analysis of the Aortic Stent Grafts Market, competition depends less on unit prices and more on clinical studies, anatomical range, device delivery, deployment technology, and physician familiarity. Medtronic plc and W. L. Gore & Associates, Inc. have a combination of broad portfolio offerings along with clinical relationship, whereas Cook Medical LLC and Terumo Aortic offer differentiation through their abdominal, thoracic, and complex aortic platforms.

Endologix LLC, MicroPort Endovascular MedTech Co., Ltd., and LifeTech Scientific Corporation are market players that focus on their device engineering and geographic growth, while Artivion, Inc. offers exposure into complex aortic interventions. Lombard Medical Technologies and Braile Biomédica S.A. offer solutions for specialist and regional requirements. The areas of investment for this business include pivotal studies, post-market evidence, custom manufacturing, and training infrastructure, which altogether create high barriers to entry.

Aortic Stent Grafts Market: Strategic Insights

Regional Insights

North America Aortic Stent Grafts Market

North America held 41.0–42.0% of global revenue in 2025 and is forecast to register a 7.0–7.4% CAGR during 2026–2034. The Aortic Stent Grafts Market is highly characterized by good imaging access, efficient referral systems, Medicare and other insurance companies’ reimbursement, and clustering of vascular surgeons in tertiary facilities. Screening and incidental discovery by means of abdominal and cardiovascular imaging contribute to elective repairs before aneurysmal rupture.

The regional demand for aortic stent grafts is moving towards smaller delivery systems, tapered thoracic stents, and grafts designed for difficult necks. Society for Vascular Surgery criteria suggest that aneurysm repair quality is directly associated with the number of procedures performed by the institution and their outcomes, thus ensuring treatment clustering in centers having experience with such cases. US registry studies involved 67,865 patients in 336 centers.

U.S. Aortic Stent Grafts Market

The US represented 83.0–87.0% of North American revenue in 2025 and is expected to grow at a 7.1–7.5% CAGR during 2026–2034. The demand is supported by large-scale academic hospitals, integration of cardiac systems, and wide availability of CT angiography. Medtronic plc, W. L. Gore & Associates, Inc., Cook Medical LLC, Terumo Aortic, Endologix LLC, and Artivion, Inc. exhibit considerable commercial or clinical development presence. Usage is progressing from conventional treatment of infrarenal aneurysms to ruptured aneurysms, thoracic dissections, difficult neck configurations, and arch disease. The regulatory environment emphasizes performance and monitoring because endoleak, migration, sac growth, and re-interventions may occur post-implantation. The 2026 clearance of NEXUS Aortic Arch Stent Graft System is an example of regulatory achievement in case of chronic dissection in the arch.

Europe Aortic Stent Grafts Market

Europe accounted for 24.0–25.0% of revenue in 2025 and is projected to record a 6.6–7.0% CAGR through 2034. Germany is spearheaded by specialized vascular centers, imaging, and significant capability for elective aneurysm repairs. Centralized purchasing and evidence-based technology assessment compel manufacturers to provide proof of durability, repeat intervention capabilities, and cost-effectiveness along with technical efficacy.

The United Kingdom gains from national screening and vascular clusters, though fiscal restraints may prolong adoption periods. France offers the combination of skilled endovascular operators and reimbursement assessment structure. Italy and Spain gain through regional referral centers and skilled cardiovascular surgeons, with divergent purchasing mechanisms causing inequity in accessing top-notch devices. Increasing demand in Europe is for low-profile, fenestrated, branched, and thoracic systems.

APAC Aortic Stent Grafts Market

Asia Pacific held 21.5–22.5% share in 2025 and is expected to expand at a 7.2–7.6% CAGR through 2034. China dominates regional income from hospitals' expanding infrastructure, local manufacturing capabilities, and rising treatment availability. The Japan market has high thoracic premium adoption through specialty centers and an older population.

South Korea and Australia have advanced procedural capabilities, whereas India has good long-term prospects as tertiary cardiovascular capabilities increase. Reimbursement and specialist availability are inconsistent as there is access through local manufacturing strategies, regulatory reforms, and physician training. Gore had launched its approved large-diameter tapered thoracic devices in Japan in March 2025.

Middle East & Africa Aortic Stent Grafts Market

The region is forecast to register a 6.0–6.4% CAGR during 2026–2034. Leading through hospital modernization, recruitment of specialists, and the development of tertiary cardiovascular services is Saudi Arabia. UAE fosters the adoption of technology through focused public and private facilities that handle complex referrals.

South Africa is the main sub-Saharan market due to the availability of vascular expertise. Rest of Middle East and Africa, however, experiences limitations relating to diagnosis, payment, and catheterization infrastructure. Funding for health by energy money in Gulf nations enables the use of hybrid operating rooms and imaging facilities, but regional growth needs training and referral management.

Segmentation Analysis

By Product

Product categories are expected to register a combined CAGR of 7.0–7.4% during 2026–2034. The scope of the Aortic Stent Grafts Market includes the high volume of infrarenal aneurysm repairs and the technically complex cases of thoracic procedures. The use of such devices is highly dependent on the anatomy of the landing zone, diameter of the access vessel, branches included, state of the rupture, delivery profile, fixation, and deployment control.

• Abdominal Aortic Stent Grafts: This category held 72.3% of revenue in 2025, reflecting established EVAR protocols, screening-supported diagnosis, extensive clinical experience, and recurring demand for main bodies, iliac limbs, cuffs, and extensions.
• Thoracic Aortic Stent Grafts: The segment represented 27.7% of 2025 revenue and carries strategic importance as treatment expands across descending thoracic aneurysms, traumatic transections, complicated dissections, and selected arch-related disease.

By End User

End-user demand is projected to advance at a combined CAGR of 6.9–7.3% during 2026–2034. The scope of the Aortic Stent Grafts Market includes the high volume of infrarenal aneurysm repairs and the technically complex cases of thoracic procedures. The use of such devices is highly dependent on the anatomy of the landing zone, diameter of the access vessel, branches included, state of the rupture, delivery profile, fixation, and deployment control.

• Hospitals: Hospitals accounted for 68.3% of 2025 revenue, supported by emergency coverage, intensive care, blood-bank access, advanced imaging, multidisciplinary aortic teams, and capacity to manage conversion or postoperative complications.
• Ambulatory Surgical Centers: These facilities represented 31.7% of revenue, with demand concentrated in selected elective pathways where reimbursement, patient stability, imaging access, and transfer agreements support safe outpatient or short-stay procedures.

Opportunity Snapshot

Aortic Stent Grafts Market Growth Drivers and Impact Analysis

Expanding Detection and Treatment of Aortic Aneurysms

Increased availability of CT scanning, ultrasound testing, and cardiovascular imaging is making the diagnosis of asymptomatic aneurysms prior to their rupture more common. Early diagnosis creates a larger group of candidates for surgical intervention through anatomical assessment and graft sizing. The commercial implications go beyond the initial graft to the iliac limb, cuff, extension, introducer sheath, guidewires, and postoperative imaging. The older population base results in more patients that would present greater physiological risks in the context of an open surgical procedure. It is in the best interest of manufacturers if the diagnostic programs include primary care, radiology, vascular surgery, and the referral centers. But the success in converting diagnosis to a procedure is based not only on disease incidence.

Clinical Preference for Minimally Invasive Aortic Repair

EVAR reduces the need for large incisions and cross-clamping of the aorta; therefore, EVAR has relevance to elderly and co-morbid patients. Hospital benefits include shortened recovery pathways and more predictable resource use despite the cost of the devices and the requirement for imaging surveillance. Such preference reinforces the demand for EVAR systems which feature small introducer size, control, sealing, and broad anatomical coverage. The benefit is seen especially in institutions where vascular surgeons perform both straightforward and complex cases in a hybrid operating room environment. EVAR does not solve the problem of lifelong surveillance since there are the issues of endoleak, migration, graft integrity, branch patency, and aneurysm sac dynamics.

Broader Device Eligibility for Complex Anatomy

Technological progress has increased the eligibility criteria in terms of patients who were previously not considered because of their small neck size, high angulation, mismatch in diameter, problems related to the iliac region, or the presence of branch vessels. The use of fenestrated, branched, tapered, and repositionable stents allows surgical plans to better match the patient's anatomy. Reduced profile solutions might eliminate access issues, whereas active fixation and controlled deployment will help achieve accurate positioning. In terms of business, this means an increased number of eligible procedures, but also the need to plan, have a broader range of products in inventory, educate physicians, etc. Custom products bring more manufacturing challenges and longer lead time, whereas off-the-shelf branched products need strong clinical data from anatomical groups.

Aortic Stent Grafts Market Future Trends

Image-Guided Personalization and Digital Procedure Planning

Leading market trends in the Aortic Stent Grafts Market will involve more sophisticated use of three-dimensional reconstruction, automated centerline measurement, anatomical simulation, and digital selection from inventory. The technologies can enhance reliability in measuring diameters, identifying landing zones, determining branches, and designing components. Manufacturers will be able to link planning solutions with their case management and production solutions, especially for fenestrated or customized stent grafts. Hospitals will be interested in solutions that help save time on planning and avoid component unavailability. The software will have to be validated properly, and doctors will need to control the process.

Expansion of Branched and Arch-Specific Endovascular Platforms

The development effort will increasingly focus on the aortic arch, ascending aorta, and thoracoabdominal portions, which have been challenging with open surgical repair. Branched devices will need to maintain cerebral or visceral perfusion while sealing, migration, stroke, and endoleak issues are kept under control. The April 2026 clearance by the FDA for use of NEXUS in cases of chronic dissection involving the aortic arch is an important regulatory benchmark for such devices. Future uptake will be initially driven from multidisciplinary centers equipped with cardiac surgery capabilities and sophisticated imaging. Commercial viability will depend on performance and ease of delivery, among other factors.

Aortic Stent Grafts Market Opportunities

Build Complex-Aortic Centers in Underserved Metropolitan Areas

Both manufacturers and health care practitioners can collaborate to create a program of complex-aortic referrals for cities having advanced imaging technology but no endovascular coordination. The program will have to include hybrid-room capacity, proctoring, inventory management, multidisciplinary review, and post-operative monitoring. A hub and spoke system can be used to transfer complex aneurysm cases and dissection cases to centers where they can be managed while routine diagnostics and monitoring can continue from the local centers. The suppliers can help in the adoption process using standard planning and outcome registries rather than product-specific training alone. This market is most prevalent in fast developing countries of Asia, Middle East, and Latin America.

Develop Lower-Profile Systems for Smaller Access Vessels

The small profile delivery system presents an actionable opportunity for treating patients who are anatomically limited to endovascular approaches due to their iliac and femoral anatomy. Priorities for investments include the development of thinner graft materials, optimized nitinol frame, flexible sheath, reduced crossing profile, and deployment system that maintains manoeuvrability despite miniaturization. The result could be a broadened patient population that includes women, small-body size individuals, as well as those with calcified and tortuous access vessels. The developers need to prove that the reduced profile has no negative impact on the radial strength, sealing capacity, resistance to fatigue, and accuracy of deployment.

Recent Developments

• April 2026: Artivion, Inc. received premarket approval application (PMA) for their NEXUS Aortic Arch System from U.S. Food and Drug Administration (FDA) developed by Endospan Ltd. ("Endospan"), Artivion's long-standing partner.
• December 2025: "W. L. Gore & Associates announced the first implantation of the investigational GORE Ascending Stent Graft in the ARISE III Trial for the treatment of an acute Type A dissection. The implant was performed at Emory University by Brad Leshnower, MD, Site Principal Investigator and Director of Thoracic Aortic Surgery and Yazan Duwayri, MD, Study Investigator and Chief of Vascular Surgery and Endovascular Therapy.
• October 2025: Medtronic plc received U.S. Food and Drug Administration (FDA) labeling approval for their Endurant stent graft system, by adding ruptured abdominal aortic aneurysm (rAAA) clinical evidence and removing the rAAA treatment warning. This FDA labeling approval makes Medtronic the first and only company to remove the rAAA warning from its stent graft system Instructions for Use (IFU), aligning innovation with real-world practices and training to empower physicians to act confidently in emergency cases.